title: Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma.
abstract: In this pilot clinical trail the efficacy of intralesional low-dose human recombinant interferon-gamma was investigated in seven outpatients with nodular basal cell carcinoma. There was no antitumor response in any case. Toxic side effects were minimal. All tumors were excised surgically 8 weeks after completion of therapy.
authors.affiliation: Department of Dermato-Venereology, Erasmus University, Rotterdam, The Netherlands.
authors.forename: B
authors.initials: B
authors.lastname: Tank
authors.forename: J M
authors.initials: JM
authors.lastname: Habets
authors.forename: B
authors.initials: B
authors.lastname: Naafs
authors.forename: O
authors.initials: O
authors.lastname: Damsma
authors.forename: E
authors.initials: E
authors.lastname: Stolz
authors.forename: T
authors.initials: T
authors.lastname: van Joost
mesh_terms: D000368:Aged; D002280:Basal Cell Carcinoma / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: D007371:Interferon-gamma